This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Johnson & Johnson’s Top Scientist to Depart
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Johnson & Johnson’s Top Scientist to Depart
Business

Johnson & Johnson’s Top Scientist to Depart

Editorial Board Published October 12, 2021
Share
Johnson & Johnson’s Top Scientist to Depart
SHARE

Johnson & Johnson’s JNJ -0.42% top scientist, who oversaw a turnaround in the company’s pharmaceutical unit and the development of a Covid-19 vaccine, will retire at the end of the year.

Contents
Newsletter Sign-upCoronavirus Briefing and Health Weekly

Paul Stoffels, who is 59 years old, will step down Dec. 31 as vice chairman of the executive committee and chief scientific officer, J&J said Tuesday.

The New Brunswick, N.J., company, which makes Band-Aid bandages and Tylenol pain reliever as well as therapies for diseases like cancer and psoriasis, didn’t immediately name a replacement.

“As a physician and a scientist, it is gratifying to see the healthcare landscape transformed as we unlock the best science and technology to deliver innovative medicines to solve the world’s toughest health challenges,” Dr. Stoffels said.

This is the second departure of a senior executive that J&J has disclosed in recent weeks. In August, the company said Alex Gorsky will retire as chief executive and serve as executive chairman, effective Jan. 3, 2022.


Newsletter Sign-up

Coronavirus Briefing and Health Weekly

Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.


J&J named longtime executive Joaquin Duato to succeed Mr. Gorsky as CEO.

Dr. Stoffels is retiring to spend more time with his family in Europe and to cut down on travel, according to a person familiar with the matter. He frequently flew back and forth between the U.S. and Europe for his J&J job duties.

Dr. Stoffels began his career as a physician in Africa focusing on tropical-disease research before joining J&J’s Janssen Pharmaceutica division in Belgium, his first stint at J&J.

In the early 1990s, he left J&J to co-found companies that would become Tibotec-Virco, a Belgian developer of antiviral drugs.

Dr. Stoffels rejoined J&J when it acquired Tibotec-Virco in 2002 and helped lead the big company’s development of HIV drugs. J&J is now a leading seller of the medicines, which have helped turn infections into a manageable condition.

He became J&J’s global head of pharmaceutical research and development at J&J in 2009 and later served as chairman of the pharmaceutical unit for several years. He has served as J&J’s chief scientific officer of J&J since 2012.

Since Dr. Stoffels took over pharmaceutical R&D in 2009, the company’s annual pharmaceutical revenue has doubled to $45.6 billion in 2020, making J&J a dominant force in the industry.

The company has made successful bets on new drugs for cancer, such as Darzalex and Zytiga, while expanding offerings for immune-mediated conditions like psoriasis.

Under Dr. Stoffels’ leadership, J&J said, its pharmaceutical R&D teams developed more than 25 new medicines, seven of which have been added to the World Health Organization’s list of essential medicines.

Dr. Stoffels pushed J&J to pursue medicines for the developing world, including one for multidrug-resistant tuberculosis and vaccines against Ebola and Covid-19.

“With Paul at the helm, Janssen rejuvenated its pipeline, launching multiple new medicines, making a difference for people all over the world,” Mr. Duato said in a press release.

Beginning in early 2020, Dr. Stoffels oversaw the development of a Covid-19 vaccine and was often the public face providing updates on J&J’s progress. The vaccine proved generally safe and effective in a large clinical trial and was authorized for use in the U.S. this past February.

Uptake of the J&J Covid-19 vaccine, however, has been less than expected because of safety concerns surrounding a rare blood-clot condition seen in some vaccine recipients as well as manufacturing problems that limited the dose supply.

Write to Peter Loftus at peter.loftus@wsj.com

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article DoorDash Introduces Search-Page Ads for Restaurants DoorDash Introduces Search-Page Ads for Restaurants
Next Article House Set to Temporarily Raise Debt Limit House Set to Temporarily Raise Debt Limit

Editor's Pick

I attempted Google’s new Search Dwell function and ended up debating an AI about books

I attempted Google’s new Search Dwell function and ended up debating an AI about books

Google’s new Search Dwell function lets customers maintain real-time voice conversations with an AI-powered model of Search The Gemini-powered AI…

By Editorial Board 6 Min Read
Valkyries convey again Chen and Bibby as EuroBasket hits roster
Valkyries convey again Chen and Bibby as EuroBasket hits roster

The Valkyries signed 2025 third-round draft decide Kaitlyn Chen and ahead Chloe…

3 Min Read
AI at Scale: Mohammed’s Revolutionary Architecture Behind the World’s Fastest Website Builder
AI at Scale: Mohammed’s Revolutionary Architecture Behind the World’s Fastest Website Builder

In an extraordinary technological breakthrough, Abdul Muqtadir Mohammed has fundamentally transformed how…

7 Min Read

Oponion

Yemen’s Houthi Rebels Claim Deadly Aerial Attacks on U.A.E. Capital

Yemen’s Houthi Rebels Claim Deadly Aerial Attacks on U.A.E. Capital

Yemen’s Houthi rebels said they were behind aerial attacks in…

January 17, 2022

The Best and Worst U.S. Airlines of 2021

The good news: Flying is more…

January 28, 2022

714 is typical Californian’s credit score rating. How does that rank?

Californians, on common, have “good” credit…

May 17, 2025

Kurtenbach: The SF Giants’ subsequent two weeks will inform us the place they stand within the NL

If the aim of a baseball…

June 2, 2025

One lifeless after small fireplace in facet yard of Harmony residence

CONCORD — An individual died Wednesday…

March 6, 2025

You Might Also Like

Exploring Royal Mail’s Use of Ambient IoT Know-how with Wiliot
Business

Exploring Royal Mail’s Use of Ambient IoT Know-how with Wiliot

Eric Casavant: The partnership is a three-phase effort, undertaken by Royal Mail and Wiliot to digitize automobiles, amenities, and supply…

6 Min Read
Airgain Launches Business’s First Commercially Obtainable Cat 1 bis Embedded Modem Licensed for Buyer Finish-Functions
Business

Airgain Launches Business’s First Commercially Obtainable Cat 1 bis Embedded Modem Licensed for Buyer Finish-Functions

New addition to the NimbeLink Skywire™ household simplifies world IoT deployments with sooner integration, decrease prices, and seamless {hardware} migration.…

4 Min Read
From Blind Spots to Insights: Smarter Asset Monitoring
Business

From Blind Spots to Insights: Smarter Asset Monitoring

By Ohad Peled, Product Advertising Supervisor at Sony Semiconductor Israel. Over the previous couple of years, asset monitoring has emerged…

9 Min Read
Contained in the Physique: How Ingestible Sensors Are Shaping the Way forward for Healthcare
Business

Contained in the Physique: How Ingestible Sensors Are Shaping the Way forward for Healthcare

Lately, the speedy evolution of expertise has dramatically remodeled healthcare. From wearable devices to AI-powered diagnostics, innovation has been on…

12 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?